Mostrar el registro sencillo del ítem
dc.contributor.author
Vazquez, Ana M.
dc.contributor.author
Hernandez, Ana M.
dc.contributor.author
Macias, Amparo
dc.contributor.author
Montero, Enrique
dc.contributor.author
Gomez, Daniel Eduardo
dc.contributor.author
Alonso, Daniel Fernando
dc.contributor.author
Gabri, Mariano Rolando
dc.contributor.author
Gomez, Roberto E.
dc.date.available
2023-05-04T18:33:27Z
dc.date.issued
2012-10
dc.identifier.citation
Vazquez, Ana M.; Hernandez, Ana M.; Macias, Amparo; Montero, Enrique; Gomez, Daniel Eduardo; et al.; Racotumomab: an anti=idiotype vaccine related to N=glycolyl=containing=gangliosides: Preclinical and clinical data; Frontiers Media; Frontiers in Oncology; 2; 10-2012; 1-6
dc.identifier.issn
2234-943X
dc.identifier.uri
http://hdl.handle.net/11336/196342
dc.description.abstract
Neu-glycolyl (NeuGc)-containing gangliosides are attractive targets for immunotherapy with anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplasmic membrane in humans, but their expression has been demonstrated in several human malignant tumors. Racotumomab is an anti-idiotype mAb specific to P3 mAb, an antibody which reacts to NeuGc-containing gangliosides, sulfatides, and other antigens expressed in tumors. Preparations containing racotumomab were able to induce a strong anti-metastatic effect in tumor-bearing mice. Different Phase I clinical trials have been conducted in patients with advanced melanoma, breast cancer, and lung cancer. The results of these clinical trials demonstrated the low toxicity and the high immunogenicity of this vaccine. The induced antibodies recognized and directly killed tumor cells expressing NeuGcGM3. A Phase II/III multicenter, controlled, randomized, double blind clinical trial was conducted to evaluate the effect of aluminum hydroxide-precipitated racotumomab vaccine in overall survival in patients with advanced non-small cell lung cancer. The clinical results of this study showed a significant clinical benefit in the patients who were treated with the anti-idiotype vaccine.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Frontiers Media
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
RACOTUMOMAB
dc.subject
VACCINE
dc.subject
GANGLIOSIDES
dc.subject
CANCER
dc.subject.classification
Biología Celular, Microbiología
dc.subject.classification
Ciencias Biológicas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.title
Racotumomab: an anti=idiotype vaccine related to N=glycolyl=containing=gangliosides: Preclinical and clinical data
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-05-03T15:35:45Z
dc.journal.volume
2
dc.journal.pagination
1-6
dc.journal.pais
Suiza
dc.description.fil
Fil: Vazquez, Ana M.. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Hernandez, Ana M.. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Macias, Amparo. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Montero, Enrique. Center of Molecular Immunology; Cuba
dc.description.fil
Fil: Gomez, Daniel Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
dc.description.fil
Fil: Alonso, Daniel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
dc.description.fil
Fil: Gabri, Mariano Rolando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
dc.description.fil
Fil: Gomez, Roberto E.. Elea Laboratories; Argentina
dc.journal.title
Frontiers in Oncology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fonc.2012.00150/
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fonc.2012.00150
Archivos asociados